



(51) International Patent Classification:

A61K 31/7105 (2006.01) C07K 16/28 (2006.01)
 A61K 35/17 (2015.01) C12N 15/62 (2006.01)
 A61P 35/00 (2006.01) C12N 15/867 (2006.01)
 C07K 14/705 (2006.01) A61K 39/00 (2006.01)
 C07K 14/725 (2006.01)

(21) International Application Number:

PCT/EP2020/052867

(22) International Filing Date:

05 February 2020 (05.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2019/053156

08 February 2019 (08.02.2019) EP

(71) Applicant: **BIONTECH CELL & GENE THERAPIES GMBH** [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: **SAHIN, Ugur**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). **OEHM, Petra**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). **RENGSTL, Benjamin**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). **REINHARD, Katharina**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). **MICHEL, Kristina**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE).

(74) Agent: **SCHNAPPAUF, Georg**; Zwicker Schnappauf & Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLS FOR THE TREATMENT OF CLDN6-EXPRESSING CANCERS

Figure 1

A)



(57) Abstract: The present disclosure relates to a chimeric antigen receptor (CAR) showing highly specific and sensitive recognition of CLDN6 expressing target cells as well as a high potential for survival and repetitive stimulation of CAR T cells.